Coastal Infrastructure California

Tidal Flooding, a Cancer Breakthrough, and the Access Question That Follows

Southern California's coastline flooded for a second consecutive day Wednesday, with record tidal levels inundating communities from Ventura County through San Diego. These are not storm surge events; they are driven by an alignment of astronomical high tides with above-average sea surface temperatures that suppress the normal variability that buffers coastal areas from peak tidal events. Infrastructure designed for historical tide ranges — storm drains, coastal roads, low-lying properties — is simply being submerged. The 'king tide' phenomenon has occurred for centuries, but roughly eight to ten inches of sea level rise over the past century means communities that previously flooded once every twenty years now flood annually, and those that flooded annually now flood monthly.

The economic exposure is substantial. Orange County alone has coastal commercial, hospitality, and residential property assessed at hundreds of billions of dollars, and flood insurance penetration in California coastal zones has historically been low. Insurance markets have moved ahead of the politics: multiple major insurers have reduced or eliminated residential coverage offerings in California coastal areas over the past three years. Congress has no active federal climate adaptation legislation, meaning states are the primary unit of adaptation policy — an equity problem with no near-term federal solution.

In health news that arrived with considerably better news, a Merck and Moderna mRNA melanoma vaccine showed a 42% reduction in recurrence or death risk in trial data published this week. The platform is the same one that produced the COVID vaccines. Experts welcoming the result are simultaneously pressing a scientifically important follow-on question: the mechanism by which it works is not yet fully understood, which matters for predicting which patients will respond and for designing the next generation of cancer vaccines. The 'recurrence or death' combined endpoint also warrants unpacking — the relative contributions of each component to the overall 42% figure carry different implications for treatment planning. A separate and unavoidable concern is cost access: mRNA cancer vaccines are currently priced at levels that make them accessible primarily to patients in wealthy healthcare systems or with comprehensive insurance. For Merck and Moderna, a successful Phase 3 result opens the path to FDA approval conversations and, if the platform proves generalizable, potential application across multiple cancer types.